
Clinical Cancer Highlights Research Highlights

November 1, 2010 • Volume 16 • Number 21

Selected Articles from This Issue



Role of GSK-3β in Bladder Cancer

Naito et al. Page 5124

The serine/threonine kinase GSK-3 β is a positive regulator of human cancer cell survival and proliferation. To explore the role of GSK-3 β in bladder cancer, Naito and colleagues determined the subcellular localization of GSK-3 β and evaluated the effect of GSK-3 inhibition. Nuclear accumulation of GSK-3 β was strongly associated with high-grade tumors, metastasis, and lower survival rates in bladder cancer patients. Further, inhibition of GSK-3 β suppressed proliferation and survival of bladder cancer cells. These results identify nuclear accumulation of GSK-3 β as a novel prognostic marker in bladder cancer, and suggest GSK-3 β as a potential therapeutic target in urothelial carcinoma.

DNA Repair Genes and Melanoma Relapse

Jewell et al. Page 5211

Prognostic and chemotherapy predictive biomarkers are needed for melanoma. In this study, Jewell and colleagues performed gene expression profiling of formalin-fixed primary melanoma tumors. They found that DNA repair genes, predominantly involved in double-strand break repair, were over-expressed in tumors from patients with reduced relapsefree survival, and in tumors with higher mitotic rate. Analysis of a subset of patients treated with chemotherapy (predominantly dacarbazine) revealed that DNA repair genes were over-expressed in tumors from patients unresponsive to chemotherapy. These findings highlight the importance of upregulation of DNA repair processes during melanoma progression and indicate a potential role in chemoresistance.

FDG-PET Imaging Predicts Sunitinib Response


Carr et al. _____Page 5260

Carr and colleagues performed a phase II trial of continuous dosing of sunitinib in patients with advanced thyroid cancer to determine disease response and toxicity. Also, an exploratory analysis of FDG-PET imaging after seven days of therapy was performed to determine if disease response could be predicted. Of 33 patients, 10 had partial responses and 16 had stable disease. Patients with RECIST response and stable disease had a significant decline in average SUVs compared to patients with progressive disease. These results suggest that FDG-PET imaging may

help identify patients unlikely to respond to tyrosine kinase inhibitor therapy.

30-Gene Chemotherapy Response Predictor in Breast Cancer

Tabchy et al. _____Page 5351



Clinically useful predictors of response to specific chemotherapy regimens in breast cancer are needed.

Tabchy and colleagues tested a 30gene predictor of pathologic complete response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, cyclophosphamide (T/FAC) chemotherapy from fine-needle biopsies of breast cancers in a prospective randomized trial. The authors found that the 30-gene predictor could identify patients with greater than average sensitivity to T/FAC chemotherapy but not to FAC treatment. To improve their clinical utility, second generation genomic predictors should be developed separately for different molecular subsets of breast cancers.



Clinical Cancer Research

Highlights of This Issue

Clin Cancer Res 2010;16:5089.

Updated version Access the most recent version of this article at:

http://clincancerres.aacrjournals.org/content/16/21/5089

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications

Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link

http://clincancerres.aacrjournals.org/content/16/21/5089.

Click on "Request Permissions" which will take you to the Copyright Clearance Center's

(CCC)

Rightslink site.